

FORM PTO-1449		US Dept. of Commerce Patent and Trademark Office		ATTORNEY DOCKET NO. 4121-135		SERIAL NO. 10/049,404	
INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)				APPLICANT Michaela Arndt		FILING DATE February 5, 2002	
				GROUP 1644		Not yet assigned.	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
C.C.	AA 5,643,759	7/1/97	Pfreundschuh				
C.C.	AB 6,294,167	9/25/01	Lindhofer et al.			Already considered	
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
C.C.	AC DE 43 37 197	10/30/93	Germany				
C.C.	AD DE 195 31 346	8/25/95	Germany				
C.C.	AE DE 198 38 967	2/6/98	Germany				
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
C.C.	AF	XP-002115487. "Bispecific CD3 X CD19 Diabody for T Cell-Mediated Lysis of Malignant Human B Cells." Kipriyanov et al. Int. J. Cancer: 77, 763-771 (1998).					
1	AG	"Anti- CD16/CD38 bispecific antibodies as possible treatment for refractory Hodgkin's Disease." Hartmann et al., Leuk & Lymph., 1998. Vol 31. patent. 385-392.					
C.C.	AH	XP 000653169. 609. Klimka et al.					
	AI	XP-002153101. "A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplanted human Hodgkin's tumors." Arndt et al. Blood, Vol. 94, No. 8 (October 15), 1999: patent 2562-2568.					
Already considered (Duplicative)							
EXAMINER a g				DATE CONSIDERED 8/11/06			